Postherpetic Neuralgia Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week, Phase 3 Study to Evaluate the Efficacy and Safety of HSK16149 Capsules in Chinese Patients With Postherpetic Neuralgia
Verified date | February 2023 |
Source | Haisco Pharmaceutical Group Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo
Status | Completed |
Enrollment | 372 |
Est. completion date | January 5, 2023 |
Est. primary completion date | December 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Signed informed consent; 2. Males or females aged 18-75 years of age inclusive; 3. Outpatient, Patients can not stay in the hospital overnight; 4. Patients must have pain present for more than 1 months after the healing of the herpes zoster skin rash; 5. At Screening, pain scale (VAS) of =40 mm; Exclusion Criteria: 1. Peripheral neuropathy or pain unrelated to PHN that may confuse the assessment of PHN; 2. Skin conditions in the area affected by neurupathy that could alter sensation; 3. Chronic systemic diseases that may affect subjects' participation in the study; 4. Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:1)Neutrophils < 1.5 × 109/L, or platelet < 90 × 109/L, or hemoglobin < 100 g/L, or 2)AST/ALT > 2.5 × upper limit of normal (ULN), or TBIL > 1.5 × ULN, or 3)Estimation of glomerular filtration rate (eGFR) < 60 mL/min / 1.73 m2, or 4)Creatine kinase > 2.0 × ULN. 5. Uncontrolled diabetes(HbA1c=11.0% at screening) ; 6. History of substance abuse or alcohol abuse; 7. Any active infections at screening; 8. HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive; 9. Inability or unwillingness to discontinue any other prohibited concomitant medications (see Section 6.3); 10. Patients who have undergone neurolytic or neurosurgical therapy 1 week before screening for postherpetic neuralgia; 11. Failure to response to previous treatment with pregabalin at doses = 300 mg/d or gabapentin at doses = 1200 mg/d for treatment of PHN; 12. History of allergic or medically significant adverse reaction to investigational products or their excipients, acetaminophen or related compounds; 13. History of suicidal behavior or attempted suicide; 14. Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period; 15. Mechanical operators who are engaged in high-altitude operations, motor vehicle driving and other dangerous machinery operators; 16. Participated in another clinical study within 30 days prior to screening; 17. Other conditions unlikely to participate in this trial. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital Of Nanchang University | Nanchang | Jiangxi |
China | Dermatology Hospital of Chinese Academy of Medical Sciences | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Haisco Pharmaceutical Group Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare the change from baseline in ADPS between HSK16149 and placebo at week 12 | The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries | Baseline and week 12 | |
Secondary | Compare the response rate between HSK16149 and placebo at week 12 (Proportion of subjects whose ADPS decreased by =30% and =50% from baseline ) | Ratio of Participants Responding to Treatment, as Measured by Average Daily Pain Score (ADPS) Reduction from Baseline. The ADPS is used to determine categorical response rates. | Baseline and week 12 | |
Secondary | Compare the change from baseline in ADPS between HSK16149 and placebo at week 1 to 12 | The mean change in average daily pain score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 [no pain] to 10 [worst possible pain]. The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries | From week 1 to week 12 | |
Secondary | Compare the change from baseline in Visual Analogue Scale(VAS) between HSK16149 and placebo at week 12 | VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain | Baseline and week 12 | |
Secondary | Compare the change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) between HSK16149 and placebo at week 12 | Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score:
Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe) Part 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain) |
Baseline and week 12 | |
Secondary | Compare the change from baseline in Average Daily Sleep interference score(ADSIS) between HSK16149 and placebo at week 12 | he sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores | Baseline and week 12 | |
Secondary | Compare the total consumption of Acetaminophen and Paracetamol and Dihydrocodeine Tartrate between HSK16149 and placebo during the trial | From week 1 to week 12 | ||
Secondary | Compare the change from baseline in EQ-5D-5L between HSK16149 and placebo at week 12 | The change from baseline in total EuroQol-5-Domain-5-Level health questionnaire | Baseline and week 12 | |
Secondary | AE(adverse event) to evaluate the safety of HSK16149 during the trial | Number and severity of AEs | From week 1 to week 12 | |
Secondary | Peak Plasma Concentration (Cmax) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia | Week 4,week 8,week 10,week 12 | ||
Secondary | Area under the plasma concentration versus time curve (AUC) of HSK16149 capsules in Chinese patients with Postherpetic Neuralgia | Week 4,week 8,week 10,week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546334 -
Erector Spinae Plane Block in Post-herpetic Neuralgia
|
N/A | |
Terminated |
NCT01744522 -
Leech Therapy for Postherpetic Neuralgia
|
N/A | |
Completed |
NCT01688947 -
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00478179 -
Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00566904 -
New Topical Treatment for Continued Pain After Shingles
|
Phase 1 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Terminated |
NCT01603394 -
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
|
Phase 4 | |
Completed |
NCT01251211 -
Botulinum Toxin in Peripheral Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01228838 -
Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00612105 -
Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)
|
Phase 2 | |
Recruiting |
NCT04560361 -
The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia
|
N/A | |
Recruiting |
NCT05568186 -
Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
|
||
Recruiting |
NCT04664530 -
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
|
Phase 4 | |
Active, not recruiting |
NCT01508676 -
Effects of Pennsaid on Clinical Neuropathic Pain
|
N/A | |
Completed |
NCT00885586 -
Acupuncture in Herpes Zoster Neuralgia (ACUZoster)
|
Phase 4 | |
Completed |
NCT00981227 -
Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
|
Phase 2 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00238511 -
An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00007501 -
Shingles Prevention Study
|
Phase 3 | |
Completed |
NCT04594226 -
Electroacupuncture Therapy for Treating Postherpetic Neuralgia
|
N/A |